Literature DB >> 2502148

Progression to AIDS and predictors of AIDS in seroprevalent and seroincident cohorts of homosexual men.

M T Schechter1, K J Craib, T N Le, B Willoughby, B Douglas, P Sestak, J S Montaner, M S Weaver, K D Elmslie, M V O'Shaughnessy.   

Abstract

As part of an ongoing prospective study of seropositive homosexual men in Vancouver, Canada, a seroprevalent cohort of 246 subjects (i.e. duration of infection unknown) and a seroincident cohort of 102 subjects (i.e. duration of infection known) were followed a median of 63 and 45 months, respectively. Follow-up with validation utilizing record linkage with the Canadian Federal Centre for AIDS registry revealed 58 and nine cases of AIDS in the seroprevalent and seroincident cohorts, respectively, through July 1988. These data yield product limit estimates of the cumulative progression rates to AIDS at 60 months of 23.0% for the seroprevalent cohort, 13.0% for the seroincident cohort, and 21.0% for the combined groups. Univariate analyses revealed the following to be statistically and clinically significant predictors of AIDS progression: low CD4 counts, low CD4/CD8 ratios, elevated immune complexes, elevated immunoglobulin G (IgG) and immunoglobulin A (IgA) levels, and low platelet counts. Cox regression revealed that elevated IgA levels, low CD4 counts, elevated immune complexes, two or more symptoms, and more than 20 male sexual partners in high-risk areas in the 5 years prior to enrollment were independent predictors of progression to AIDS over the subsequent 5 years. A multivariate risk function based on the latter five variables delineated low-, medium- and high-risk groups whose 5-year progression rates to AIDS were 6.7, 15.6 and 64.4%, respectively. The high-risk group contained 75% of all subjects who progressed to AIDS. Only 6% of the high-risk group would have qualified for zidovudine therapy under current guidelines at the beginning of the observation period.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1989        PMID: 2502148     DOI: 10.1097/00002030-198906000-00002

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  8 in total

1.  Influence on survival of p24 antigen levels in patients with AIDS or advanced AIDS related complex treated with zidovudine.

Authors:  L Zamora; J M Gatell; J M Barrera; G Ercilla; C Gil; E Buira; J M Miro; E Soriano
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-12       Impact factor: 3.267

2.  Improving the prognostic value of CD4+ count using IgA and clinical signs in HIV-seropositive i.v. drug users.

Authors:  F Montella; P Pezzotti; F Di Sora; O Recchia; F Lauria; G Rezza
Journal:  Infection       Date:  1997 Mar-Apr       Impact factor: 3.553

3.  A simple clinical staging system that predicts progression to AIDS using CD4 count, oral thrush, and night sweats.

Authors:  L Rabeneck; M M Crane; J M Risser; C E Lacke; N P Wray
Journal:  J Gen Intern Med       Date:  1993-01       Impact factor: 5.128

4.  The cost effectiveness of antiretroviral regimens for the treatment of HIV/AIDS.

Authors:  A H Anis; D Guh; R S Hogg; X H Wang; B Yip; K J Craib; M V O'Shaughnessy; M T Schechter; J S Montaner
Journal:  Pharmacoeconomics       Date:  2000-10       Impact factor: 4.981

5.  Use of dried blood spot specimens in the detection of human immunodeficiency virus type 1 by the polymerase chain reaction.

Authors:  S Cassol; T Salas; M Arella; P Neumann; M T Schechter; M O'Shaughnessy
Journal:  J Clin Microbiol       Date:  1991-04       Impact factor: 5.948

6.  Use of CD4 lymphocyte count to predict long-term survival free of AIDS after HIV infection.

Authors:  A N Phillips; C A Sabin; J Elford; M Bofill; G Janossy; C A Lee
Journal:  BMJ       Date:  1994-07-30

Review 7.  Markers predicting progression of human immunodeficiency virus-related disease.

Authors:  C M Tsoukas; N F Bernard
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

8.  Rectal gonorrhoea as an independent risk factor for HIV infection in a cohort of homosexual men.

Authors:  K J Craib; D R Meddings; S A Strathdee; R S Hogg; J S Montaner; M V O'Shaughnessy; M T Schechter
Journal:  Genitourin Med       Date:  1995-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.